Citurgia Biochemicals Limited reported a widened net loss for the financial year ended March 31, 2026, as the company recorded zero income from operations for the period. The net loss for the year stood at ₹74.25 lakh, an increase from the net loss of ₹42.31 lakh reported in the previous year ended March 31, 2025. For the quarter ended March 31, 2026, the company reported a net loss of ₹25.82 lakh, compared to a net loss of ₹11.93 lakh in the corresponding quarter of the previous year.

The company's equity share capital remained constant at ₹2,641.91 lakh across the reported periods. Earnings per share (EPS) for the year ended March 31, 2026, was reported at (0.000) on both a basic and diluted basis, consistent with the EPS reported for the financial year 2025. The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 30, 2026.

Financial Performance Summary

The following table outlines the key financial figures for Citurgia Biochemicals Limited for the quarter and year ended March 31, 2026, and the corresponding periods in the previous year:

Regulatory Disclosures

The audited financial results are an extract of the detailed format filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditor of the company has carried out the audit report of the financial results. The complete format of the quarterly financial results is available on the websites of the stock exchanges and the company's official website.

Citurgia Biochemicals Limited reported a net loss of ₹74.25 lakh for the financial year ended March 31, 2026, widening from a net loss of ₹42.31 lakh in the previous year. The company recorded zero revenue from operations for the period, while total expenses increased to ₹74.25 lakh from ₹42.31 lakh in FY25. The Board of Directors approved the audited standalone financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026.

The statutory auditors, M/s. G.P. Keshri & Associates, issued an unmodified audit report on the financial results. The company reported a net loss of ₹25.82 lakh for the quarter ended March 31, 2026, compared to a net loss of ₹11.93 lakh in the corresponding quarter of the previous year. Total expenses for the quarter stood at ₹25.82 lakh, up from ₹11.93 lakh in the same period last year.

Financial Performance

The company's financial results for the year ended March 31, 2026, reflect a continued period of operational inactivity with respect to revenue generation. The primary components of the expenses included employee benefit expenses, depreciation, and other costs.

Assets and Liabilities

As of March 31, 2026, the company's total assets stood at ₹1,047.04 lakh, a decrease from ₹1,076.40 lakh in the previous year. The equity position showed a negative balance of ₹773.41 lakh, compared to a negative balance of ₹699.16 lakh in the prior year.

The cash flow statement indicated a net increase in cash and cash equivalents of ₹0.81 lakh for the financial year, bringing the closing balance to ₹12.69 lakh. The trading window for the company's equity shares, which was closed from April 1, 2026, will open 48 hours after the financial results are declared to the stock exchanges.